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Abstract 
OBJECTIVE: The objective of this systematic review is to determine whether or not dabigatran 
150 mg twice daily is non-inferior to warfarin for the prevention of stroke in those with atrial 
fibrillation with similar rates of bleeding events.  
 
STUDY DESIGN: Review of 3 English language primary studies. All three trials were 
randomized controlled trials which were blinded for those receiving dabigatran and un-blinded 
for those receiving warfarin.  
 
DATA SOURCES: Articles were found using PUBMED and COCHRANE databases. 
 
OUTCOME MEASURED: The primary outcomes of these studies were either incidence of 
stroke or systemic embolism and/or major bleeding events. 
 
RESULTS: The RE-LY study determined that rates of stroke or systemic embolism were 1.11% 
per year in the group who received 150 mg of dabigatran twice daily and 1.69% per year in those 
who received dose adjusted warfarin (CI =95%; P=<0.0001). The incidence of major bleeding 
was 3.11% per year in those who received dabigatran 150 mg twice daily and 3.36% per year in 
the warfarin group (P=0.003). The RE-COVER study found that recurrent venous 
thromboembolism occurred in 2.4% of patients who received dabigatran and 2.1% of those who 
received warfarin (CI= 95%, P= <0.001). Incidence of major bleeding was found in 1.6% of 
patients in the dabigatran 150 mg group and a slightly higher percentage of 1.9% of those in the 
warfarin group (CI=95%). The PETRO study determined that in the 150 mg dabigatran group 
without aspirin, 9% of patients reported clinically relevant bleeding with zero thromboembolic 
events. In patients who received dose adjusted warfarin without aspirin, 5.7% of patients 
experienced clinically relevant bleeding with also no reported thromboembolic events (P=0.01).  
 
CONCLUSION: The systemic review of all three randomized controlled trials indicates that 
dabigatran 150 mg twice a day is a safe, effective, and more convenient alternative to warfarin to 
prevent stroke in patients with atrial fibrillation.  
 
KEYWORDS: Atrial fibrillation, dabigatran, warfarin, stroke.  
INTRODUCTION 
 
 Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting more 
than two million patients throughout the United States.1  Each year, more than 300,000 new 
cases are diagnosed.2  Atrial fibrillation comprises nearly $6 – 7 billion in direct medical 
expenditures and accounts for approximately 350,000 hospitalizations annually.3 Research has 
shown that when comparing medical costs of a non-AF patient to an AF patient, total annual 
direct medical costs of those with AF are close to 5 times greater than that of those without the 
arrhythmia.4 Medical costs in patients with this condition may be so high secondary to the nature 
and risks of the arrhythmia.  
In episodes AF, the normal electrical impulses which are generated through the sinoatrial 
node become disorganized by electrical impulses that originate in other areas of the heart, 
possibly the pulmonary veins. This “chaotic” electrical activity results in the muscle of the atria 
fibrillating instead of producing a coordinated contraction of the chambers. Unbalanced 
conduction of the ventricles also produces an irregularly irregular ventricular rate. Atrial 
fibrillation can be acute, occurring in episodes lasting only minutes to weeks, or may be chronic, 
becoming permanent in nature.5 
Many patients are asymptomatic during an episode of AF. Others may have more marked 
symptoms such as palpitations, syncope, chest pain, or shortness of breath.  Atrial fibrillation is 
commonly diagnosed through a simple electrocardiogram which will show absence of P-waves 
and the presence of an irregularly irregular ventricular rate. Risk factors for developing AF 
include heart failure, hypertensive cardiovascular disease, coronary artery disease, valvular heart 
disease, and recent myocardial infarction.6 
AF is commonly treated with medications to control heart rate and rhythm to revert the 
patient back to normal sinus rhythm. Some surgical or catheter based therapies can also be used.  
Because up to 5% of patients with chronic atrial fibrillation have at least one embolic episode per 
year, there is a need for these patients to be anticoagulated.7  Currently, warfarin, a vitamin K 
antagonist, is the first line treatment being used for prophylactic anticoagulation in this 
population. However, due to increased risk of patient hemorrhage during usage, monthly 
laboratory monitoring and numerous drug and food interactions, a new oral anticoagulant drug is 
needed that has a similar or improved safety profile, as well as better convenience for patients 
who must be on lifelong anticoagulant therapy. Dabigatran is a new oral direct thrombin 
inhibitor that is being evaluated for the prevention of stroke in those patients with AF with a 
similar incidence of hemorrhage.  
OBJECTIVE 
 
 The objective of this systematic review is to determine whether or not dabigatran 150mg 
is non-inferior to warfarin for the prevention of stroke in those with atrial fibrillation with a 
similar safety profile. To date, there are few anticoagulant drugs, other than warfarin, that are 
approved to prevent stroke in patients with AF. Dabigatran is the first oral direct thrombin 
inhibitor that has been approved to compete with warfarin to prevent stroke in those with AF 
with similar frequency of bleeding.   
METHODS 
 
The three studies that are included in this review are randomized controlled trials 
comparing the efficacy of dabigatran 150 mg to dose adjusted warfarin for the prevention of 
stroke in those atrial fibrillation with similar incidence of hemorrhage. 
Connolly et al.  conducted the RE-LY study, a randomized controlled trial to assess the 
efficacy of dabigatran 150 mg versus warfarin. The trial was non-inferior, double blinded for 
those in the dabigatran group and unblinded for those in the warfarin group due to the need for 
adjusted INR levels. The study focused on 18,113 patients with atrial fibrillation documented on 
echocardiography with one of the following: previous stroke or TIA, left ventricular ejection 
fraction less than 40%, New York Heart Association Class II or higher, age of 75, or age of 64 – 
74 with diabetes, hypertension, or coronary artery disease.  The intervention addressed in the 
study included dabigatran 150 mg twice daily to prevent stroke or systemic embolism in those 
with atrial fibrillation. The comparison group was dose adjusted warfarin.  The primary 
outcomes of this study were incidence of stroke or systemic embolism, with secondary efficacy 
endpoints consisting of major bleeding, hemorrhagic stroke, and mortality rate.   
Shulman at el.  conducted the RE-COVER study, a double blinded randomized controlled 
trial to determine the efficacy of dabigatran 150mg versus warfarin for the treatment of acute 
venous thromboembolism as well as rates of hemorrhage. This study included 2,539 patients 18 
years of age or older who had acute, symptomatic, objectively verified proximal deep vein 
thrombosis of the legs or pulmonary embolism and for whom 6 months of anticoagulant therapy 
was considered to be an appropriate treatment. Dabigatran 150 mg twice daily, after a median of 
9 days of initial parenteral anticoagulation, was the intervention addressed in this study. The 
comparison group was comprised of dose adjusted warfarin after initial parenteral 
anticoagulation.  The primary outcome measured in this study was 6-month incidence of 
confirmed venous thromboembolism. Secondary outcomes were major bleeding events, acute 
coronary syndromes, other adverse events, and results of liver function tests.  
Ezekowitz et al. conducted a similar randomized controlled trial which was double blind 
in respect to dabigatran, but open label regarding aspirin and warfarin. The population addressed 
in the PETRO study was patients with atrial fibrillation at high risk for thromboembolic events 
or AF with coronary artery disease plus 1 or more of the following: hypertension, diabetes, 
symptomatic heart failure, left ventricular dysfunction, or previous stroke or TIA. Dabigatran 
was administered at 50 mg, 150 mg, or 300 mg, twice daily with either no aspirin, 81 mg or 325 
mg aspirin once daily. The dabigatran 150 mg dose twice daily without aspirin was the main 
focus for this review. These interventions were compared to dose adjusted warfarin. The primary 
outcome addressed was frequency of bleeding events and secondary outcomes were incidence of 
stroke and/or systemic thromboembolism.  
These studies were found by the author using PubMed and Cochrane databases. The key 
words dabigatran, warfarin and atrial fibrillation were used in the literature searches to find 
articles that were published in English in peer-reviewed journals dated between  2007 – 2009. 
The articles were chosen if they were relevant, valid, and the outcomes of the studies were 
comprised of evidence that mattered to the patients (POEMS – Patient Oriented Evidence that 
Matters).  The articles selected were those that met the following criteria: POEM, randomized 
controlled trial, a diagnosis of atrial fibrillation based upon electrocardiogram, or a primary 
outcome of stroke or major bleeding. Any studies not meeting these criteria were excluded from 
this review. P-values, number needed to treat (NNT), number needed to harm (NNH), relative 
risk reduction (RRR), absolute risk reduction (ARR), control event rate (CER), and experimental 
event rate (EER) were the statistics used and reported in the studies. Table 1 shows the 
demographics of the three studies included in this review.  
 
Table 1. Demographics of included studies 
Study Type # Pts Age (yrs) Inclusion Criteria Exclusion Criteria W/D Intervention 
Connolly 
(2009) 
RE-LY 
Double 
blind RCT 
with 
respect to 
dabigatran
; 
unblinded 
in respect 
to 
warfarin  
18,113 Mean age 71 -Patients with AF 
documented on EKG 
with 1 of the 
following: 
-Previous stroke or 
transient ischemic 
attack 
-LFEV less than 40% 
-New York Heart 
Association Class II 
or higher  
-Age of 75  
-Age of 64 – 74 with 
DM, HTN, or CAD 
-Presence of severe 
valve disorder 
-Stroke w/in 14 days 
or severe stroke 
with in 6 mo before 
screening 
-Condition that 
increased risk of 
hemorrhage  
-CrCl <30 
-Acute liver disease 
-Pregnancy  
 
 
0 Dabigatran 150 
mg BID 
Schulman 
(2009) 
RE-COVER 
Double 
blind RCT 
2,550 55.0±15.8 
Dabigatran 
 
54.4±16.2 
Warfarin  
 
Patients 18 years of 
age or older who had 
acute, symptomatic, 
objectively verified 
proximal deep vein 
thrombosis of the 
legs or pulmonary 
embolism and for 
whom 6 months of 
anticoagulant therapy 
was considered to be 
an appropriate 
treatment  
 
-Symptoms longer 
than 14 days 
- PE with instability 
-Other indication for 
warfarin 
-Unstable CV 
disease 
-High bleeding risk 
-Liver disease with 
AST > 2x upper 
limit 
-CrCl <30 
-Pregnancy 
-Need for 
antiplatelet therapy 
-CI to heparin or 
contrast  
5 Dabigatran 
150mg BID 
Ezekowitz 
(2007) 
PETRO 
Double 
blind RCT 
in respect 
to 
dabigatran
; 
unblinded 
in respect 
to 
warfarin 
and ASA 
502 70.9 ±7.9 
years in 
patients with 
CAD 
 
68.0 ±8.8 
years in those 
without CAD 
-Patients with AF at 
high risk for 
thromboembolic 
events 
-AF with CAD plus 1 
of the following: 
-HTN, DM, 
symptomatic HF, LV 
dysfunction, previous 
stroke or TIA 
-Mitral stenosis 
-Prosthetic heart 
valves 
-Cardioversion 
-Recent MI, stroke 
or TIA 
Coronary stent in 
last 6 mo 
-CI to 
anticoagulation 
-severe hemorrhage 
in last 6 mo 
-Renal impairment 
-Abnl liver function 
-Pregnancy 
-Investigation drug 
use in last 30 days 
65 Dabigatran 50 
mg, 150 mg, or 
300 mg BID, 
with either no 
aspirin, 81 mg 
or 325 mg 
aspirin daily 
OUTCOMES MEASURED 
 
 The outcomes of interest in the clinical trials varied according to each study. However, 
each study included outcomes, whether primary or secondary, that will be the focus of this 
review.  
In the RE-LY study, the primary outcome measured was incidence of stroke or systemic 
embolism. The primary safety outcome was rate of major hemorrhage. Incidence of stroke was 
documented by sudden onset of a focal neurologic deficit in a location consistent with the 
territory of a major cerebral artery. The stroke was then categorized as ischemic, hemorrhagic, or 
unspecified. Occurrence of a systemic embolism was documented through imaging, surgery, or 
autopsy.  Secondary outcomes consisted of major bleeding, hemorrhagic stroke, and mortality 
rate.  Major bleeding or hemorrhage was documented by reduction in hemoglobin of at least 
2g/L, transfusion of at least 2 units of blood, or symptomatic bleeding in a critical area or organ. 
In the RE-COVER trial, the primary study outcome was 6-month incidence of recurrent, 
symptomatic, objectively confirmed venous thromboembolism and related deaths. Symptoms 
suggestive of recurrent venous thromboembolism were evaluated with the use of the same 
diagnostic methods that had been used for the initial diagnosis. Secondary outcomes were major 
bleeding events, acute coronary syndromes, other adverse events, and results of liver function 
tests. Bleeding was defined as major if it was clinically overt and if it was associated with a 
decrease in hemoglobin of at least 2g/L, resulted in the need for transfusion of 2 or more units of 
red cells, if it involved a critical site, or if the bleeding was fatal. 
In the PETRO study,  the primary outcome addressed was frequency of bleeding events 
classified as fatal or life threatening retroperitoneal, intracranial, intraocular, or intraspinal 
bleeding; or bleeding requiring surgery or transfusion of greater than 2 units associated with a 
reduction of hemoglobin greater than 2g/L. Secondary efficacy endpoints were incidence of 
stroke defined as acute onset of focal neurologic deficit of vascular origin lasting greater than 24 
hours and/or systemic thromboembolism defined as an acute non-intracerebral or noncoronary 
vascular event.  
RESULTS 
 
 All three randomized controlled trials evaluated the efficacy of dabigatran 150 mg twice 
daily to prevent stroke in patients in AF or measured rates of major and minor bleeding 
compared with dose adjusted warfarin.  
 In the RE-LY study a total of 18,113 patients were enrolled, all of which had a mean age 
of 71 years and a mean CHADS2 score of 2.1 (the CHADS2 score is a measure of the risk of 
stroke in which CHF, HTN, and age of 75 years or older, and DM are each given 1 point and 
previous stroke or TIA are each given 2 points).8 The median duration of follow-up was 2.0 
years with 99.9% of patients achieving complete follow-up.  Rates of the primary outcome of 
stroke or systemic embolism were 1.11% per year in the group who received 150 mg of 
dabigatran twice daily and 1.69% per year in those who received dose adjusted warfarin. A 
confidence interval of 95% and a P-value of <0.0001 for non-inferiority was used for this data. 
The NNT was determined to be – 173, signifying that for every 173 patients treated with 
dabigatran, 1 less patient experienced stroke or hemorrhage compared with warfarin. The 
incidence of major bleeding was 3.11% per year in those who received dabigatran 150 mg twice 
daily and 3.36% per year in the warfarin group. The occurrence of hemorrhagic stroke was 
determined to be 0.38% per year in the warfarin group and 0.10% in the dabigatran group at a p-
value of <0.0001. Mortality rate was found to be 3.64% per year with 150 mg of dabigatran 
twice daily, whereas warfarin mortality was 4.13% per year at a p-value of 0.13.  Major vascular 
events, major bleeding, and death comprised the net clinical benefit outcome. The rate of this 
outcome in the warfarin group was 7.64% per year and 6.91% per year in those given 150 mg of 
dabigatran at a CI of 95% and a p-value of 0.10 (Table 2).  The NNH in this group was 
determined to be -400, thus, for every 400 patients treated with dabigatran, one less patient had 
an incidence of major bleeding, hemorrhagic stroke, or mortality compared to warfarin. 
Table 2. Efficacy and Bleeding Outcomes of the RE-LY Study 
Event Dabigatran 150 mg 
N= 6076 
Dose Adjusted Warfarin 
N= 6022 
 # of patients %/year P-value # of patients %/year P-value 
Stroke or 
systemic 
embolism 
134 1.11 <0.0001 199 1.69 <0.0001 
Major 
Bleeding 
375 3.11 0.003 397 3.36 0.003 
Hemorrhagic 
Stroke 
12 0.10 <0.0001 45 0.38 <0.0001 
Mortality 
Rate 
438 3.64 0.13 487 4.13 0.13 
Net clinical 
benefit 
832 6.91 0.10 901 7.64 0.10 
 
 In the RE-COVER trial, a total of 2,564 patients were enrolled, with a total of 1,274 
patients in the dabigatran 150 mg group and 1,265 in the warfarin group. Incidence of the 
primary outcome, recurrent venous thromboembolism, occurred in 2.4% of patients who 
received dabigatran and 2.1% of those who received warfarin at a CI of 95% and p-value of 
<0.001. The NNT in this group was 334. For every 334 people treated with dabigatran, 1 more 
person had an occurrence of confirmed venous thromboembolism, compared to warfarin. 
Incidence of major bleeding, which is of more concern for this review, was found in 1.6% of 
patients in the dabigatran 150 mg group and a slightly higher percentage of 1.9% of those in the 
warfarin group. For every 334 people treated with dabigatran, one less person experienced major 
bleeding, acute coronary symptoms, and/or elevated liver function tests in comparison to 
warfarin. Sites of major bleeding for the dabigatran groups included gastrointestional (9 events), 
urogenital (5), intraarticular (1), intramuscular (1) or another site (6). For the warfarin group, 
major sites of bleeding included urogenital (6), gastrointestinal (5), intraarticular (4), intracranial 
(3), intramuscular (3), or another site (4).  A total of 5.6% of patients who received dabigatran 
compared to 8.8% of patients who were given warfarin experienced major or clinically relevant 
non-major bleeding (Table 3).  
Table 3. Efficacy and Bleeding Outcomes of the RE-COVER Study 
Outcome Dabigatran 150 mg 
twice daily 
(N=1274) 
Warfarin 
 
(N=1265) 
Confidence Interval  
Venous thromboembolism 
or related death 
30 patients 
2.4% 
 
27 patients 
2.1% 
 
 
95% 
 
Major Bleeding Events 20 patients 
1.6% 
24 patients 
1.9% 
95% 
Major or clinically 
relevant non-major 
bleeding 
71 patients 
5.6% 
111 patients 
8.8% 
 
95% 
 
 
 In the PETRO trial, 502 patients were randomized who had atrial fibrillation for a median 
duration of 4 years. The primary outcome was frequency of bleeding events. In the 150 mg 
dabigatran group without aspirin, 9% of patients reported clinically relevant bleeding with zero 
thromboembolic events. In patients who received dose adjusted warfarin without aspirin, 5.7% of 
patients experienced clinically relevant bleeding with also no reported thromboembolic events at 
a p-value of 0.01 (Table 4). The NNH for this study was -8 signifying that for every 8 patients 
treated with dabigatran without aspirin, 1 less patient experienced a bleeding event when 
compared to dose adjusted warfarin without aspirin.  
 
Table 4. Major or clinically relevant bleeding episodes and thromboembolic events in PETRO 
 Number of 
patients 
Major 
Bleeding 
Clinical 
Relevant plus 
Major 
Bleeding 
Thromboembolic 
Events 
Dabigatran 150 
mg BID 
100 0 9 (9%) 0 
Warfarin 70 0 4 (5.7%) 0 
Because in all three trials the data was dichotomous, the control event rate (CER), 
experimental event rate (EER), absolute benefit increase (ABI), relative benefit increase (RBI), 
number needed to treat (NNT) and number needed to harm (NNH) were each calculated.  The 
CER is the percentage of patients who responded to the dose adjusted warfarin whereas the EER 
is the percentage who responded to the 150 mg dabigatran. The ABI is the increase of a good 
event as a result of dabigatran. The RBI is the proportional increase in the rates of good 
outcomes between the warfarin and dabigatran group. The results of number needed to treat and 
number needed to harm determines the number of people needed to be treated to prevent 1 event 
of stroke or embolic event or to cause 1 event of major hemorrhage. Table 5 represents this data 
that was calculated for all three of the trials described above.  
Table 5. Treatment analysis for patients receiving dabigatran versus warfarin for prevention of 
stroke  
Study CER EER RBI ABI NNT and 
NNH 
RE-LY 1.96% 
3.36% 
1.11% 
3.11% 
-34.3% 
-7.4% 
-0.58% 
-0.25% 
-173   (NNT) 
-400   (NNH) 
RE-COVER 2.1% 
1.90% 
2.4% 
1.60% 
14.3% 
-15.8% 
3.00% 
-3.00% 
334     (NNT) 
-334   (NNH) 
PETRO 17.1% 15.0% -12.3% -21.0% -8       (NNH) 
DISCUSSION 
 
 Dabigatran etexilate is a prodrug of dabigatran, a reversible competitive inhibitor of 
thrombin activity. Dabigatran is able to inhibit both free and clot bound thrombin, as well as 
inhibit thrombin’s activation of platelets.9 The drug requires no laboratory monitoring and carries 
minimal drug and food interactions when compared with warfarin, making dabigatran an 
attractive alternative to patients and prescribers. The most common adverse events that have 
been associated with the use of dabigatran are bleeding and gastrointestinal symptoms including 
dyspepsia, nausea, diarrhea, abdominal pain, and gastrointestinal bleeding.10 The RE-LY study 
demonstrated a statistically significant decrease in the rates of stroke and systemic embolism 
when compared with warfarin. The RE-COVER and PETRO study each exemplified the safety 
of dabigatran when compared to warfarin with a statistically significant decrease in major 
bleeding events.  
All three studies presented in this review can be termed valid for many reasons. They 
were randomized controlled trials whose outcomes were presented as dichotomous data, and the 
studies were double-blinded in regards to the dabigatran group. There were also a minimal 
number of patients who were lost to follow-up. Because there was a small sample size of patients 
in the PETRO dabigatran 150 mg group, the results may have been skewed.  
CONCLUSION 
 
This review indicates that dabigatran 150 mg twice a day is a safe and effective alternative to 
warfarin to prevent stroke in patients with atrial fibrillation. In all three studies, dabigatran 
150mg was found to be non-inferior to warfarin in respect to stroke prevention and incidence of 
bleeding. In the RE-LY study, dabigatran 150 mg was found to be superior when to compared to 
warfarin regarding rates of stroke and systemic embolism. Higher and lower doses of dabigatran 
have been investigated, however, results showed that the lower doses were not as effective in 
preventing stroke whereas higher doses had increased incidence of major bleeding rates. Future 
studies should compare the efficacy of dabigatran versus another new oral thrombin inhibitor, 
rivaroxaban, for the prevention of stroke in patients with AF.  
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